Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis |
| |
Authors: | Monson Nancy L Cravens Petra Hussain Rehana Harp Christopher T Cummings Matthew de Pilar Martin Maria Ben Li-Hong Do Julie Lyons Jeri-Anne Lovette-Racke Amy Cross Anne H Racke Michael K Stüve Olaf Shlomchik Mark Eagar Todd N |
| |
Institution: | Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America. |
| |
Abstract: | Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephalomyelitis (EAE) model of MS in mice that express human CD20, Rituximab administration rapidly depleted peripheral B cells and strongly reduced EAE severity. B cell depletion was also associated with diminished Delayed Type Hypersensitivity (DTH) and a reduction in T cell proliferation and IL-17 production during recall immune response experiments. While Rituximab is not considered a broad immunosuppressant, our results indicate a role for B cells as a therapeutic cellular target in regulating encephalitogenic T cell responses in specific tissues. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|